September 2, 2008
Debiopharm and EPFL Sign Research Project Agreement
Debiopharm Group, which focuses on serious medical conditions and particularly oncology, has signed a research project agreement with Ecole Polytechnique Federale de Lausanne, aimed at the identification of novel small molecules and peptides that interfere with pathways controlling cell fate specification.
The project, named Debio 0826, could lead to the development of potential therapeutic compounds and to the identification of new targets to fight cancer stem cells.
It is reported that Debio 0826 will benefit from the multiple molecular and genetic tools generated by Dr Radtke's group over the past 10 years, as well as the expertise of Dr Turcatti in the molecular screening field.
Kamel Besseghir, CEO of Debiopharm, said: "Targeting pathways controlling cell fate specification could generate innovative anticancer drugs with antitumoral, antimetastatic and antiangiogenic properties to treat tumors that are currently resistant to standard therapies."